Quantification of measurable residual disease in patients with multiple myeloma based on the IMWG response criteria

Abstract Stringent complete response (sCR) is defined as a deeper response than complete response (CR) in multiple myeloma. Whether achieving sCR correlates with better survival remains controversial. We evaluated the outcomes in patients with intact immunoglobulin multiple myeloma (IIMM) and light...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kentaro Narita, Daisuke Miura, Takafumi Tsushima, Toshiki Terao, Ayumi Kuzume, Rikako Tabata, Masami Takeuchi, Kosei Matsue
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/8020879372c0409c95c76aeeaeaff2c8
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:8020879372c0409c95c76aeeaeaff2c8
record_format	dspace
spelling	oai:doaj.org-article:8020879372c0409c95c76aeeaeaff2c82021-12-02T17:55:13ZQuantification of measurable residual disease in patients with multiple myeloma based on the IMWG response criteria10.1038/s41598-021-94191-82045-2322https://doaj.org/article/8020879372c0409c95c76aeeaeaff2c82021-07-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-94191-8https://doaj.org/toc/2045-2322Abstract Stringent complete response (sCR) is defined as a deeper response than complete response (CR) in multiple myeloma. Whether achieving sCR correlates with better survival remains controversial. We evaluated the outcomes in patients with intact immunoglobulin multiple myeloma (IIMM) and light chain multiple myeloma (LCMM) who achieved a very good partial response (VGPR) or better. Multicolour flow cytometry was used to assess the depth of response. LCMM patients with sCR had significantly lower measurable residual disease (MRD) levels than those with CR (median MRD: 7.9 × 10–4 vs. 5.6 × 10–5, P < 0.01). Nonetheless, no significant difference was observed in MRD levels across the responses in groups of patients with IIMM (VGPR vs. CR: 3.5 × 10–4 vs. 7.0 × 10–5, P = 0.07; CR vs. sCR: 7.0 × 10–5 vs. 5.4 × 10–5, P = 0.81. In accordance with MRD levels, the median overall survival of patients with sCR was significantly longer (sCR, CR, VGPR; not reached, 41 months, and 58 months, respectively; VGPR vs. CR, P = 0.83; CR vs. sCR, P = 0.04) in LCMM, but not in IIMM (sCR, CR, VGPR; not reached, 41 months, and not reached, respectively; VGPR vs. CR, P = 0.59; CR vs. sCR; P = 0.10). Our results show that sCR represents a deeper response that correlates with longer survival in patients with LCMM, but not IIMM.Kentaro NaritaDaisuke MiuraTakafumi TsushimaToshiki TeraoAyumi KuzumeRikako TabataMasami TakeuchiKosei MatsueNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-7 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Kentaro Narita Daisuke Miura Takafumi Tsushima Toshiki Terao Ayumi Kuzume Rikako Tabata Masami Takeuchi Kosei Matsue Quantification of measurable residual disease in patients with multiple myeloma based on the IMWG response criteria
description	Abstract Stringent complete response (sCR) is defined as a deeper response than complete response (CR) in multiple myeloma. Whether achieving sCR correlates with better survival remains controversial. We evaluated the outcomes in patients with intact immunoglobulin multiple myeloma (IIMM) and light chain multiple myeloma (LCMM) who achieved a very good partial response (VGPR) or better. Multicolour flow cytometry was used to assess the depth of response. LCMM patients with sCR had significantly lower measurable residual disease (MRD) levels than those with CR (median MRD: 7.9 × 10–4 vs. 5.6 × 10–5, P < 0.01). Nonetheless, no significant difference was observed in MRD levels across the responses in groups of patients with IIMM (VGPR vs. CR: 3.5 × 10–4 vs. 7.0 × 10–5, P = 0.07; CR vs. sCR: 7.0 × 10–5 vs. 5.4 × 10–5, P = 0.81. In accordance with MRD levels, the median overall survival of patients with sCR was significantly longer (sCR, CR, VGPR; not reached, 41 months, and 58 months, respectively; VGPR vs. CR, P = 0.83; CR vs. sCR, P = 0.04) in LCMM, but not in IIMM (sCR, CR, VGPR; not reached, 41 months, and not reached, respectively; VGPR vs. CR, P = 0.59; CR vs. sCR; P = 0.10). Our results show that sCR represents a deeper response that correlates with longer survival in patients with LCMM, but not IIMM.
format	article
author	Kentaro Narita Daisuke Miura Takafumi Tsushima Toshiki Terao Ayumi Kuzume Rikako Tabata Masami Takeuchi Kosei Matsue
author_facet	Kentaro Narita Daisuke Miura Takafumi Tsushima Toshiki Terao Ayumi Kuzume Rikako Tabata Masami Takeuchi Kosei Matsue
author_sort	Kentaro Narita
title	Quantification of measurable residual disease in patients with multiple myeloma based on the IMWG response criteria
title_short	Quantification of measurable residual disease in patients with multiple myeloma based on the IMWG response criteria
title_full	Quantification of measurable residual disease in patients with multiple myeloma based on the IMWG response criteria
title_fullStr	Quantification of measurable residual disease in patients with multiple myeloma based on the IMWG response criteria
title_full_unstemmed	Quantification of measurable residual disease in patients with multiple myeloma based on the IMWG response criteria
title_sort	quantification of measurable residual disease in patients with multiple myeloma based on the imwg response criteria
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/8020879372c0409c95c76aeeaeaff2c8
work_keys_str_mv	AT kentaronarita quantificationofmeasurableresidualdiseaseinpatientswithmultiplemyelomabasedontheimwgresponsecriteria AT daisukemiura quantificationofmeasurableresidualdiseaseinpatientswithmultiplemyelomabasedontheimwgresponsecriteria AT takafumitsushima quantificationofmeasurableresidualdiseaseinpatientswithmultiplemyelomabasedontheimwgresponsecriteria AT toshikiterao quantificationofmeasurableresidualdiseaseinpatientswithmultiplemyelomabasedontheimwgresponsecriteria AT ayumikuzume quantificationofmeasurableresidualdiseaseinpatientswithmultiplemyelomabasedontheimwgresponsecriteria AT rikakotabata quantificationofmeasurableresidualdiseaseinpatientswithmultiplemyelomabasedontheimwgresponsecriteria AT masamitakeuchi quantificationofmeasurableresidualdiseaseinpatientswithmultiplemyelomabasedontheimwgresponsecriteria AT koseimatsue quantificationofmeasurableresidualdiseaseinpatientswithmultiplemyelomabasedontheimwgresponsecriteria
_version_	1718379117198442496

Quantification of measurable residual disease in patients with multiple myeloma based on the IMWG response criteria

Ejemplares similares